Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

S.J & G. Fazul Ellahie (pvt) limited.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000083 193 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx193product presentations
G68generic molecules
DF7dosage-form groups
TA12therapeutic areas
PKR193current price records
REG160registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixS.J & G. Fazul Ellahie (pvt) limited.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026Anti-infectives113 · 59%Gastrointestinal & hepatology21 · 11%CNS & mental health16 · 8%Vitamins, minerals & nutrition15 · 8%Cardiovascular7 · 4%Pain & musculoskeletal7 · 4%Respiratory & allergy5 · 3%Other therapeutic areas9 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioS.J & G. Fazul Ellahie (pvt) limited.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026193presentationsTablet70 · 36%Injection64 · 33%Capsule20 · 10%Suspension17 · 9%Infusion10 · 5%Syrup9 · 5%Other forms3 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionS.J & G. Fazul Ellahie (pvt) limited.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026178comparable productsBelow market median41 · 23%Near market median90 · 51%Above market median47 · 26%Company median price position+1.4%Lowest-price equivalents15Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsS.J & G. Fazul Ellahie (pvt) limited.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026Neutro Pharma (Pvt.) Ltd.,41 shared60% overlapMediate Pharmaceutical Pvt Ltd38 shared56% overlapNabiqasim Industries (Pvt) Ltd.,37 shared54% overlapBosch Pharmaceuticals (Pvt) Ltd.37 shared54% overlapBio-Labs(Pvt) Ltd37 shared54% overlapMacter International Limited35 shared51% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Formulation footprint

Dosage forms

Tablet70 products
Injection64 products
Capsule20 products
Suspension17 products
Infusion10 products
Syrup9 products
Solution3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4123% of comparable products
Near market median90within ±5% of median
Above market median4726% of comparable products
Lowest-price equivalents15ties included
Company median price position +1.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Registration numbers160
Price-history records221
Products with price history27
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

193 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Nezkil Nezkil Linezolid 600 mg Tablet 10's 035263 PKR 3,556.94 PKR 355.69/tablet 10% below median
Nezkil Nezkil Linezolid 200 mg IV infusion 100 ml 048802 PKR 813.03 PKR 8.13/mL 16% above median
Novus Sofosbuvir 400 mg Tablet 28's 080794 PKR 11,384.80 PKR 406.60/tablet 5% below median
Orilan Ribavirin 400 mg Tablet 10's 083292 PKR 176.03 PKR 17.60/tablet Near median
Oxyclor Hydroxychloroquine 200 mg Tablet 30's 085954 PKR 528.10 PKR 17.60/tablet 22% above median
Oxytocin Oxytocin 10 IU/mL Injection 100 x 1 ml 011050 PKR 267.64 PKR 2.68/mL 9% below median
Paniv Tenofovir disoproxil 300 mg Tablet 30's 058542 PKR 6,789.23 PKR 226.31/tablet Near median
Phenytal Fosphenytoin sodium 100 mg Injection 2 ml 061470 PKR 288.46 PKR 144.23/mL No comparator
Phenytal Fosphenytoin sodium 750 mg fosphenytoin sodium (equiv. phenytoin sodium 500 mg) Injection 10 ml 061471 PKR 1,442.29 PKR 144.23/mL No comparator
Plasare Paroxetine 20 mg Tablet 20's 034877 PKR 1,411.01 PKR 70.55/tablet Near median
Plasare Paroxetine 30 mg Tablet 10's 047150 PKR 444.81 PKR 44.48/tablet No comparator
Plasare Paroxetine 20 mg Tablet 10's 034877 PKR 720.18 PKR 72.02/tablet Near median
Plasare CR Paroxetine 25 mg Tablet 30's 108515 PKR 1,630.46 PKR 54.35/tablet Near median
Pyrazinamide Pyrazinamide 500 mg Tablet 500's 008950 PKR 2,663.33 PKR 5.33/tablet Near median
Pyrazinamide Pyrazinamide 500 mg Tablet 50's 008950 PKR 266.32 PKR 5.33/tablet Near median
Rexamol Paracetamol 500 mg Tablet 1000's 005083 PKR 486.08 PKR 0.49/tablet 86% below median
Rexaphenicol Chloramphenicol 125 mg/5 mL Suspension 60ml 002207 PKR 75.66 PKR 1.26/mL 204% above median
Rilonav Lopinavir + Ritonavir 200 mg + 50 mg Tablet 120's 104373 PKR 10,982.67 PKR 91.52/tablet Near median
Seretron Ondansetron 8 mg/4 mL Injection 4mlx1's 135159 PKR 517.00 PKR 129.25/mL 48% below median
Setak Escitalopram 5 mg Tablet 14's 047420 PKR 635.45 PKR 45.39/tablet 75% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.